\n\n
Key developments this week include a projected market surge to $17.6 billion by 2031, a $7.7 billion informatics outlook for 2030, and unprecedented activity from frontier AI labs. Anthropic, OpenAI, ByteDance’s Anew Labs and Isomorphic Labs have each launched or expanded life‑science‑focused teams and models—OpenAI even listed a new gpt‑rosalind‑discovery model on its pricing page—signalling a shift from generic AI to purpose‑built drug‑discovery engines.
Why it matters: The influx of AI designs is turning wet labs into data‑generation factories. GenScript’s capacity jumped to about 8,000 designs per day (targeting 16,000 by year‑end) and Twist Bioscience (TWST) forecasts triple‑digit growth in AI‑enabled synthesis orders for FY26‑27. This “bottleneck trade” mirrors the semiconductor era, where early‑stage suppliers become the next “shovel sellers.”
What to watch next: Isomorphic Labs aims to place its first AI‑designed molecules into human trials by late‑2027, and subsequent clinical outcomes (2028‑2030) will reveal whether AI‑derived drugs outperform conventional candidates. Continued investment growth—McKinsey reports AI‑drug‑discovery spending rose to $8.4 billion in 2025—will likely fund further model releases and expand the wet‑lab infrastructure needed to feed the AI feedback loop. [[1, 2, 3, 4]]